Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival

Blood

Volumn 103, Issue 7, 2004, Pages 2771-2778

  Chiaretti, Sabina ^b   Li, Xiaochun ^b   Gentleman, Robert ^b   Vitale, Antonella ^b   Vignetti, Marco ^b   Mandelli, Franco ^b   Ritz, Jerome ^a   Foa, Robin ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PREDICTION; PRIORITY JOURNAL; REFRACTORY PERIOD; T CELL LEUKEMIA; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 1642317557     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3243     Document Type: Article

References (53)

1. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3995-4019.
2. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90:4243-4251.
3. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
4. -)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood. 1989;73:1247-1258.
5. Bowtell DD. Options available-from start to finish-for obtaining expression data by microarray. Nat Genet. 1999;21:25-32.
6. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996;14:457-460.
7. Zhang W, Laborde PM, Coombes KR, Berry DA, Hamilton SR. Cancer genomics: promises and complexities. Clin Cancer Res. 2001;7:2159-2167.
8. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826.
9. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
10. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539-548.
11. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
12. Miyazato A, Ueno S, Ohmine K, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood. 2001;98:422-427.
13. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
14. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
15. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
16. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
17. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
18. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
19. Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981.
20. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
21. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
22. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99:282-289.
23. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98:31-36.
24. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
25. Ihaka GR, Gentleman R. R: a language for data analysis and graphics. J Comput Graphical Stat. 1996;5:299-314.
26. Venables WN, Ripley BD. Modern Applied Statistics with S-PLUS. New York, NY: Springer; 1999.
27. Cutrona G, Tasso P, Dono M, et al. CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer. 2002;86:1776-1785.
28. -) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucemies. Leuk Lymphoma. 1998;28:329-342.
29. Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1990;75:166-173.
30. Shtivelman E, Cohen FE, Bishop JM. A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure. Proc Natl Acad Sci U S A. 1992;89:5472-5476.
31. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol. 2000;27:540-559.
32. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87.
33. Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood, 2003;101:2693-2703.
34. di Celle PF, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood. 1996;87:4382-4389.
35. di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood. 1994;84:220-228.
36. Molica S, Vitelli G, Levato D, Levato L, Dattilo A, Gandolfo GM. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia. Haematologica. 1999;84:208-211.
37. Liu J, Zeng H, Zhang Y. [Study on the expression of interleukin-8 and its receptors in acute leukemia]. Zhonghua Xue Ye Xue Za Zhi. 1999;20:24-26.
38. Kudoh J, Wang Y, Minoshima S, et al. Localization of the human AHNAK/desmoyokin gene (AHNAK) to chromosome band 11q12 by somatic cell hybrid analysis and fluorescence in situ hybridization. Cytogenet Cell Genet. 1995;70:218-220.
39. 2+ homeostasis regulation by S100B. J Biol Chem. 2001;276:23253-23261.
40. Sussman J, Stokoe D, Ossina N, Shtivelman E. Protein kinase B phosphorylates AHNAK and regulates its subcellular localization. J Cell Biol. 2001;154:1019-1030.
41. Mills GB, Schmandt R, McGill M, et al. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem. 1992;267:16000-16006.
42. Hogg D, Guidos C, Bailey D, et al. Cell cycle dependent regulation of the protein kinase TTK. Oncogene. 1994;9:89-96.
43. Castillo AR, Meehl JB, Morgan G, Schutz-Geschwender A, Winey M. The yeast protein kinase Mps1p is required for assembly of the integral spindle pole body component Spc42p. J Cell Biol. 2002;156:453-465.
44. Moingeon P, Chang HC, Sayre PH, et al. The structural biology of CD2. Immunol Rev. 1989;111:111-144.
45. Lobach DF, Hensley LL, Ho W, Haynes BF. Human T cell antigen expression during the early stages of fetal thymic maturation. J Immunol. 1985;135:1752-1759.
46. Sasada T, Reinherz EL. A critical role for CD2 in both thymic selection events and mature T cell function. J Immunol. 2001;166:2394-2403.
47. Yang H, Reinherz EL. Dynamic recruitment of human CD2 into lipid rafts. Linkage to T cell signal transduction. J Biol Chem. 2001;276:18775-18785.
48. Dustin ML. Membrane domains and the immunological synapse: keeping T cells resting and ready. J Clin Invest. 2002;109:155-160.
49. Bowden G, LA Diaz, LL Li, Fox D. Epitopes and functional responses defined by workshop anti-CD2 in monoclonal antibodies. In: Schlossman SF BL, Gilks W, Harlan JM, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. Vol. 1. Oxford, United Kingdom: Oxford University Press; 1995:346-347.
50. Schmidt RE, Michon JM, Woronicz J, Schlossman SF, Reinherz EL, Ritz J. Enhancement of natural killer function through activation of the T11 E rosette receptor. J Clin Invest. 1987;79:305-308.
51. Siliciano RF, Pratt JC, Schmidt RE, Ritz J, Reinherz EL. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature. 1985;317:428-430.
52. Uckun FM, Steinherz PG, Sather H, et al. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1996;88:4288-4295.
53. Ballerini P, Blaise A, Busson-Le Coniat M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood. 2002;100:991-997.